FLT3 and acute myeloid leukemia: The first FLT3 inhibitor to be FDA approved in 2017 was midostaurin, which evolved the treatment landscape by being the first targeted therapy for AML to improve overall survival and is now approved as a first-line treatment in addition to standard chemotherapy in those with either an FLT3-TKD or FLT3-ITD mutation [49].